Market Cap 23.41B
Revenue (ttm) 9.68B
Net Income (ttm) 1.63B
EPS (ttm) N/A
PE Ratio 9.33
Forward PE 10.48
Profit Margin 16.87%
Debt to Equity Ratio 0.35
Volume 1,659,800
Avg Vol 1,697,018
Day's Range N/A - N/A
Shares Out 146.70M
Stochastic %K 93%
Beta 0.10
Analysts Sell
Price Target $176.07

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
testius
testius Nov. 13 at 10:36 AM
$IFRX Biogen $BIIB could still acquire INF904 in nefrology, Biogen already showed interest in that indication, while Inflarx hinted to it too.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:34 AM
$BIIB: The last close at $159.39 indicates a strong position within the recent trading range, with the 60D high at $160.2 acting as a resistance level. The RSI at 69.76 suggests that the stock is approaching overbought territory, which may lead to a pullback. However, the stock remains above both the 30-day MA of $150.52 and the 50-day MA of $146.93, indicating a bullish trend in the medium term. Directional bias is cautiously bullish, but with an awareness of potential short-term corrections due to the elevated RSI. Suggested entry is at $158.00 to capitalize on potential upward momentum. Set a stop loss at $155.00 to manage risk. Target 1 is $162.00, just above the 60D high, and Target 2 is $165.00, allowing for further gains if the bullish trend continues. Monitor market conditions closely, as a reversal could occur if the RSI declines significantly. https://privateprofiteers.com
0 · Reply
Chingying
Chingying Nov. 12 at 9:47 PM
$BIIB To $171 before pullback.
0 · Reply
doctordinero
doctordinero Nov. 12 at 4:49 PM
$GILD Was in the 60s for about 10 years and then off it went. Patience is king. $BIIB and $BMRN next. GLTA. $SPY
0 · Reply
Albino_Trader123
Albino_Trader123 Nov. 12 at 4:22 PM
$REGN $BIIB $GILD $AMGN safe place to hide for now until tech finds stabilizes...
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:10 AM
$BIIB: The last close at $159.39 indicates a strong position within the recent trading range, with the 60D high at $160.2 acting as a resistance level. The RSI at 69.76 suggests that the stock is approaching overbought territory, which may lead to a pullback. However, the stock remains above both the 30-day MA of $150.52 and the 50-day MA of $146.93, indicating a bullish trend in the medium term. Directional bias is cautiously bullish, but with an awareness of potential short-term corrections due to the elevated RSI. Suggested entry is at $158.00 to capitalize on potential upward momentum. Set a stop loss at $155.00 to manage risk. Target 1 is $162.00, just above the 60D high, and Target 2 is $165.00, allowing for further gains if the bullish trend continues. Monitor market conditions closely, as a reversal could occur if the RSI declines significantly. https://privateprofiteers.com
0 · Reply
Chartist0_0
Chartist0_0 Nov. 11 at 7:49 PM
$BIIB added more. 235$ in 2026
0 · Reply
Chartist0_0
Chartist0_0 Nov. 11 at 3:16 PM
$BIIB calls on weakness, target 235$. Summer expiration.
0 · Reply
Chingying
Chingying Nov. 11 at 6:47 AM
$BIIB 11/10/25 Per Pharma Voice’s article, sales of AZ drug leqembi and kinsula are rising.
0 · Reply
biolover
biolover Nov. 10 at 2:36 PM
$VKTX Names would be $VRTX $INSM $BIIB that want to get to mega size
0 · Reply
Latest News on BIIB
Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 9:16 PM EDT - 13 days ago

Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript


Biogen's Comeback: Why The Bulls Are Finally Winning Again

Oct 9, 2025, 10:54 AM EDT - 4 weeks ago

Biogen's Comeback: Why The Bulls Are Finally Winning Again


BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

Oct 3, 2025, 8:50 AM EDT - 5 weeks ago

BIIB Stock: Is Biogen Still A Buy After The 14% Spike?


Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 2:24 PM EDT - 3 months ago

Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript


testius
testius Nov. 13 at 10:36 AM
$IFRX Biogen $BIIB could still acquire INF904 in nefrology, Biogen already showed interest in that indication, while Inflarx hinted to it too.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:34 AM
$BIIB: The last close at $159.39 indicates a strong position within the recent trading range, with the 60D high at $160.2 acting as a resistance level. The RSI at 69.76 suggests that the stock is approaching overbought territory, which may lead to a pullback. However, the stock remains above both the 30-day MA of $150.52 and the 50-day MA of $146.93, indicating a bullish trend in the medium term. Directional bias is cautiously bullish, but with an awareness of potential short-term corrections due to the elevated RSI. Suggested entry is at $158.00 to capitalize on potential upward momentum. Set a stop loss at $155.00 to manage risk. Target 1 is $162.00, just above the 60D high, and Target 2 is $165.00, allowing for further gains if the bullish trend continues. Monitor market conditions closely, as a reversal could occur if the RSI declines significantly. https://privateprofiteers.com
0 · Reply
Chingying
Chingying Nov. 12 at 9:47 PM
$BIIB To $171 before pullback.
0 · Reply
doctordinero
doctordinero Nov. 12 at 4:49 PM
$GILD Was in the 60s for about 10 years and then off it went. Patience is king. $BIIB and $BMRN next. GLTA. $SPY
0 · Reply
Albino_Trader123
Albino_Trader123 Nov. 12 at 4:22 PM
$REGN $BIIB $GILD $AMGN safe place to hide for now until tech finds stabilizes...
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:10 AM
$BIIB: The last close at $159.39 indicates a strong position within the recent trading range, with the 60D high at $160.2 acting as a resistance level. The RSI at 69.76 suggests that the stock is approaching overbought territory, which may lead to a pullback. However, the stock remains above both the 30-day MA of $150.52 and the 50-day MA of $146.93, indicating a bullish trend in the medium term. Directional bias is cautiously bullish, but with an awareness of potential short-term corrections due to the elevated RSI. Suggested entry is at $158.00 to capitalize on potential upward momentum. Set a stop loss at $155.00 to manage risk. Target 1 is $162.00, just above the 60D high, and Target 2 is $165.00, allowing for further gains if the bullish trend continues. Monitor market conditions closely, as a reversal could occur if the RSI declines significantly. https://privateprofiteers.com
0 · Reply
Chartist0_0
Chartist0_0 Nov. 11 at 7:49 PM
$BIIB added more. 235$ in 2026
0 · Reply
Chartist0_0
Chartist0_0 Nov. 11 at 3:16 PM
$BIIB calls on weakness, target 235$. Summer expiration.
0 · Reply
Chingying
Chingying Nov. 11 at 6:47 AM
$BIIB 11/10/25 Per Pharma Voice’s article, sales of AZ drug leqembi and kinsula are rising.
0 · Reply
biolover
biolover Nov. 10 at 2:36 PM
$VKTX Names would be $VRTX $INSM $BIIB that want to get to mega size
0 · Reply
dogDazeSummer
dogDazeSummer Nov. 10 at 12:46 PM
$IFRX its a buy under $3 IMO The mechanism is officially validated $BIIB $AMGN $ABBV next entrant ?
0 · Reply
dogDazeSummer
dogDazeSummer Nov. 10 at 10:59 AM
$IFRX Nice to see pre market volume holding average weighted pricing around $1.70 ~ ($1.6-$2) The more notional volume at higher levels helps not only liquidity but creates technical attraction from investors we never expected. We still need “investable data”- (data a phara can see getting FDA approved via efficacy/ MOA /safety) on 1 of the 3 options. As Niels has said, entities are under NDA & have been looking at various aspects. Some PG, HS, CSU maybe all. Those NDA’s expire the very second the data drops in next 90 minutes ——and “they” likely have a plan. Ex: buy (or sell) as much as we can up to $1.75, $2, $2.5 etc Defining “they:” 1. Existing institutional shareholders; likely to add on good data 2. New institutional bio / non bio funds; 3. Entities like $ABBV $AMGN $BIIB $RHHBY 4. Retail like us who have been waiting and are the largest subset of 1-4, ~75%
1 · Reply
dogDazeSummer
dogDazeSummer Nov. 8 at 2:02 PM
$IFRX Niels stated we’re talking to BP under NDA (of course) /Cantor Tom stated BP is “well aware of the value” of the C5a axis and its potential, / Cantor Dr Maurer (God rest his soul) was friends with Niels and was very confident CSU was directly tied to C5a axis - KOL from his ofc? Gaping PG wounds didn’t close 100%, - hints of viability w possible partner under nda The underlying drug is approved in Europe / EMA here. $AMGN has fda approval w same MOA -$400M/ yr- but 1 small drawback is liver toxicity, which we solved for. $BIIB $1.1b value 1 drug 3 yrs behind. Inflarx doesnt brag/ pump/ leak nor guarantee anything. The KOL mention can imply 1 or more based on wording, imo Each indication is $1B to us (not TAM) Traders created vol AH but a fund gobbled until exactly to $2.00? Who cld that fund be? Red Apples w 9.9% stakes on Monday ? Why $2? *Manner* of highly organized and synchronized con call vs ->PR on PG screams! what’s new in the 4:05 data drop?
1 · Reply
testius
testius Nov. 8 at 4:12 AM
$IFRX Biogen $BIIB is still hunting for "a couple more" C5a companies "by end of the year". Their last licensing, from Vanqua, an early stage company - earlier than Inflarx - valued total payments of 1 billion. A market cap of 1 billion means for Inflarx some 15 USD per share.
1 · Reply
testius
testius Nov. 8 at 4:12 AM
$IFRXBIOGEN $BIIB is still hunting for "a couple more" C5a companies "by end of the year". Their last licensing, from Vanqua, an early stage company - earlier than Inflarx - valued total payments of 1 billion. A market cap of 1 billion means for Inflarx some 15 USD per share.
0 · Reply
testius
testius Nov. 8 at 4:06 AM
$IFRXBIOGEN $BIIB is hunting for "a couple more" C5a companies by end of year. Their last licensing from Vanqua, an early stage company, earlier than Inflarx, valued payments in total of 1 billion. A 1 billion market cap means for Inflarx about 15 USD per share.
0 · Reply
RunnerSignals
RunnerSignals Nov. 7 at 8:48 PM
Analysts Go Bullish on $BIDU $VOD $LAC $BIIB $U Wall Street's changing its tune on these names. Read the full breakdown 👇 https://stocksrunner.com/news/2025-11-07-stock-upgrades-today-wall-street-analysts-signal-strong-buys
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Nov. 7 at 2:36 PM
$BIIB RSI: 71.04, MACD: 1.9374 Vol: 3.34, MA20: 148.09, MA50: 145.20 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RunnerSignals
RunnerSignals Nov. 7 at 5:41 AM
Fresh upgrades dropping! $BIIB $CRL $JKHY $RBC $SMCI check the story here... https://stocksrunner.com/news/2025-11-06-fresh-stock-upgrades
0 · Reply
dogDazeSummer
dogDazeSummer Nov. 6 at 5:42 PM
$IFRX Japanese study Gil was referencing that’s concerning $AMGN around avacopan. And influencing $BIIB to purchase PMX205 The 2nd generation orals INF904 and PMX205 don’t have the safety issues: https://ard.eular.org/article/S0003-4967(25)04113-5/abstract
0 · Reply
dogDazeSummer
dogDazeSummer Nov. 6 at 2:16 PM
$MLTX rejected $MRK offer at $60 months back yet raised $75M today at $10.50 w 7m newly issued shares. Pride, Ego, Greed and bias can get the best of us - but learn from other failures. Their drug had a high placed effect seen over and over in immuno-derm. Osonelokimab's safety is decent in HS, but tied to IL-17 class risks, while INF904's selectivity could make it preferable if Phase 2 data confirm low AE rates. For HS, treatment choice will depend on individual factors (infection history) and $IFRX pending data - but the differentiated MOA is much needed. Who else want to join part now that Moonlake is in “crescent status”? $BIIB $PFE
2 · Reply
topstockalerts
topstockalerts Nov. 6 at 1:44 PM
Stifel upgraded Biogen from Hold to Buy in a Thursday note, raising its price target to $202 from $144, citing an improving risk/reward profile for the stock due to multiple clinical catalysts and a potential "narrative shift" in Alzheimer's disease. "This is not a recommendation based on the core business," wrote analyst Paul Matteis, noting that Biogen's third-quarter results were mixed, and the firm expects the fourth quarter to be "barely acceptable." Instead, Stifel sees upside potential over the next 12 months driven by developments in Biogen's Alzheimer’s pipeline and beyond. According to Stifel, Biogen’s shares could benefit from "the potential success of LLY’s TB3 trial, which could fundamentally change how patients, doctors, and investors think about abeta antibodies," as well as the "likely approval for the initiation of lecanemab SQ," which could alleviate current treatment bottlenecks. $LLY $IONS $BIIB
0 · Reply